Life Science Washington Institute ’s Post

Great to see our Washington Competes winner Theresa Deisher of AVM Biotechnology at the National Institutes of Health Office of Extramural Research BIO booth. Suggest heading over to learn about how AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T-like immune cells. These TCR bispecific immune cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and clinical data indicate that these cells could play a significant role in several diseases and conditions.

Partillion Bioscience Opens Pre-Orders for Nanovial Multicell Assay Kits at SLAS 2025 https://lnkd.in/g4Mfxxxf LOS ANGELES, Jan. 27, 2025 /PRNewswire/ — Partillion Bioscience Corporation (“Partillion”), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody Discovery Kits. The Multicell Assay platform, which enables [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

Our CEO Marianne D. De Backer, MSc, PhD, MBA, joined an insightful panel at Longwood Healthcare Leaders to discuss what is next in developing targeted therapies in #oncology.     Marianne highlighted the potential of masked T-cell engagers in cancer therapy and the emerging role of new technology such as the protease-cleavable masking platform to improve targeting. The panel also discussed the importance of innovative approaches in potentially improving patient outcomes and reducing off-tumor toxicity.    #PatientsAreWaiting #Cancer #TCellEngagers #LongwoodHealthcareLeaders #JPM25 

I’m thrilled to announce the emergence of Bonito Biosciences, a new biotechnology venture co-founded by myself and Brant Binder, and funded by three institutional co-investors alongside ourselves. Building on the successes of our prior companies, X-Chem, Inc., X-BODY, Inc., and ZebiAI, Inc., Bonito Biosciences is dedicated to solving one of the most critical challenges in medicine today: tissue-selective drug delivery for macromolecules, specifically oligonucleotides.   At Bonito, we’ve assembled an exceptionally talented team of scientists who have invented a groundbreaking platform of technologies to discover our own therapeutic molecules. This platform enables the discovery of small molecule, peptide, and antibody agents that can be directly conjugated to their therapeutic payload and targeted to any cell type or tissue of interest. Our mission is to revolutionize the delivery of macromolecular therapies and unlock their full potential for patients in need.   It’s an honor to be on this journey with such a highly experienced team led by our CSO, Steve Shamah, and I’m excited for what’s to come as we chart new territory in precision drug delivery.   We look forward to sharing more about Bonito Biosciences and our progress as we grow. For now, I invite you to connect, follow, or reach out to learn more about our mission. Here’s to the future of innovation in biotech!   #BonitoBiosciences #DrugDelivery #BiotechInnovation #Oligonucleotides #NewBeginnings #LifeSciences #JPMorganHealthCareConference

Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation https://lnkd.in/gwVD-TNM A-Alpha Bio, a Seattle-based biotechnology company, announced the Department of Defense has awarded the company another $14.5M to accelerate its antibody discovery and optimize for biothreats. According to A-Alpha Bio cofounder and CEO, David Younger, PHD, “We’ve measured 10 million interactions in this collaboration and have focused so far on three pathogenic families. This extension of funding will allow us to really broaden both our potential impact on pandemic preparedness and our interest in training more generalizable models. Having an interaction space that covers more pathogen diversity is exactly what we’re interested in doing.” The post Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Partillion Bioscience Opens Pre-Orders for Nanovial Multicell Assay Kits at SLAS 2025 https://lnkd.in/g4Mfxxxf LOS ANGELES, Jan. 27, 2025 /PRNewswire/ — Partillion Bioscience Corporation (“Partillion”), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody Discovery Kits. The Multicell Assay platform, which enables [...]

Originating from the lab of Prof. Satpal Virdee at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, Outrun Therapeutics has developed a proprietary, high throughput platform which enables rapid identification of novel inhibitors of E3 ligases thereby dramatically reducing their discovery time.                                                                        Our novel platform also utilises engineered protein sensors (EPS) to uncover the underlying, detailed biochemistry of E3 ligases. This allows for the discovery of drugs with superior binding, specificity, and activity, and is a scalable strategy for the development of next-generation small molecule drugs targeting E3 ligases. Read more on what we do via the link to our website in the comments! #drugdiscovery #biotech #e3ligase #proteinstabilisation

Nobel laureate David Baker launched Archon Biosciences out of stealth to introduce a new class of biologics. Driven by AI-guided protein design, Archon has developed Antibody Cages (AbCs)—precisely engineered structures aimed at treating diseases that conventional therapies have struggled to address. With $20 million in seed funding led by Madrona Venture Labs, alongside DUMAC and Washington Research Foundation, Archon is prepared to advance its AI-based antibody structures into the therapeutic realm. James Lazarovits (CEO of Archon) describes AbCs as a way to enable greater control over therapeutic delivery and engagement with disease targets, potentially broadening treatment options for complex conditions. Archon’s approach exemplifies how AI is enabling significant progress in biologics, reinforcing its role in the future of drug discovery. George Ueda Craig Halder University of Washington Alexandria Real Estate Equities, Inc. Sahsen Ventures, LLC Pack Ventures Cornucopian Capital #Biopharma #Biotech #AIinBiotech #DrugDiscovery #ProteinDesign #Innovation #AIinHealthcare #BiotechInnovation

Twelve days until ELRIG UK Drug Discovery 2024. Please reach out to our CSO Tilmann Burckstummer or BD Manager Henrik Schmidt who will be at the conference and represent Myllia Biotechnology with a booth (B-12). Tilmann Burckstummer will present a Technology Spotlight Talk at 2.40pm in Auditorium 2. The talk will be entitled "Dual CRISPR Screens to enable Combination Therapies". In addition, the Myllia team will present three posters: Poster 1: “Design of highly efficient sgRNA libraries through comprehensive feature analysis” Poster 2: “A genome-wide CROP-Seq screen reveals mediators of T cell signaling” Poster 3: “Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing” #elrig #mylliabio #elrigdrugdiscovery2024

𝐍𝐞𝐰 𝐇𝐨𝐫𝐢𝐳𝐨𝐧𝐬 𝐢𝐧 𝐁𝐢𝐨𝐭𝐞𝐜𝐡: 𝐇𝐨𝐰 𝐀𝐈 𝐢𝐬 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬! - David Baker’s team at the University of Washington’s Institute for Protein Design recently won a Nobel Prize for AI-designed proteins. James Lazarovits and George Ueda, co-founders of Archon Biosciences, are advancing this work with "antibody cages" (AbCs) that use AI-generated proteins to control antibody distribution and engagement precisely, potentially transforming targeted therapeutics. Article in the comments below 👇🏼 #AiBiotech #Biotech #MasonHarding